Santarus, Inc. (SNTS) - Financial and Strategic SWOT Analysis Review

Summary

Santarus, Inc. (Santarus) is a specialty biopharmaceutical company. It acquires, develops and commercializing pharmaceutical products. The company’s marketed products consists of Uceris (budesonide) extended release tablets 9 mg, Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) Tablets, Fenoglide (fenofibrate) Tablets and Zegerid (omeprazole/sodium bicarbonate) capsules and powder for oral suspension. Santarus' product pipeline comprises Ruconest (recombinant human C1esterase inhibitor), Rifamycin SV MMX and SAN-300 (anti-VLA-1 antibody).

Santarus, Inc. Key Recent Developments

Mar 04, 2013: Santarus Reports Revenue Of $218m In 2012
Nov 07, 2012: Santarus Reports Revenue Of $54.7m In Q3 2012
Aug 07, 2012: Santarus Reports Revenue Of $47.2m In Q2 2012
May 08, 2012: Santarus Reports Revenue Of $45.9m In Q1 2012
Mar 05, 2012: Santarus Reports Revenue Of $42.6m In Q4 2011

This comprehensive SWOT profile of Santarus, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. SHOW LESS READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
Santarus, Inc. - Key Facts
Santarus, Inc. - Key Employees
Santarus, Inc. - Key Employee Biographies
Santarus, Inc. - Major Products and Services
Santarus, Inc. - Pharmaceutical Pipeline Products Data
Santarus, Inc., Pipeline Products by Therapy Area
Santarus, Inc., Pipeline Products by Development Phase
Santarus, Inc. - History
Santarus, Inc. - Company Statement
Santarus, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Santarus, Inc. - Business Description
Santarus, Inc. - Corporate Strategy
Santarus, Inc. - SWOT Analysis
SWOT Analysis - Overview
Santarus, Inc. - Strengths
Strength - Partnerships and Alliances
Strength - Focused Research and Development Activities
Strength - Strong Financial Performance
Santarus, Inc. - Weaknesses
Weakness - Legal Proceedings
Weakness - Business Concentration: The US
Santarus, Inc. - Opportunities
Opportunity - Strong Product Pipeline
Opportunity - Growth Prospects: Emerging Markets
Opportunity - Market Potential: Metabolic Disorders
Santarus, Inc. - Threats
Threat - Competitive Pressure
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Santarus, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Santarus, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Santarus, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Santarus, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Santarus, Inc., Recent Developments
Mar 04, 2013: Santarus Reports Revenue Of $218m In 2012
Nov 07, 2012: Santarus Reports Revenue Of $54.7m In Q3 2012
Aug 07, 2012: Santarus Reports Revenue Of $47.2m In Q2 2012
May 08, 2012: Santarus Reports Revenue Of $45.9m In Q1 2012
Mar 05, 2012: Santarus Reports Revenue Of $42.6m In Q4 2011
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Santarus, Inc., Key Facts
Santarus, Inc., Key Employees
Santarus, Inc., Key Employee Biographies
Santarus, Inc., Major Products and Services
Santarus, Inc., Number of Pipeline Products by Therapy Area
Santarus, Inc., Number of Pipeline Products by Development Stage
Santarus, Inc., Pipeline Products By Therapy Area and Development Phase
Santarus, Inc., History
Santarus, Inc., Subsidiaries
Santarus, Inc., Key Competitors
Santarus, Inc., Ratios based on current share price
Santarus, Inc., Annual Ratios
Santarus, Inc., Interim Ratios
Santarus, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Santarus, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Santarus, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Santarus, Inc., Pipeline Products by Therapy Area
Santarus, Inc., Pipeline Products by Development Phase
Santarus, Inc., Performance Chart (2008 - 2012)
Santarus, Inc., Ratio Charts
Santarus, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Santarus, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Par Pharmaceutical Companies, Inc.
XenoPort, Inc.
Salix Pharmaceuticals, Ltd.
POZEN Inc.
Gaymar Industries, Inc.
CytoGenix, Inc.
Depomed, Inc.